Peptide insights, analyzed
Independent, data-driven independent journalism on peptides and metabolic compounds. Discussion analyses, comparisons, and plain-language explainers — laboratory use only.
CJC-1295 + Ipamorelin in 2026: What Researchers Get Right (and Wrong)
Deep dive into the CJC-1295 + Ipamorelin research stack: receptor logic, formulation confusion, evidence limits, and protocol quality standards that matter.
Retatrutide and the Rise of Triple Agonist Peptides: What Researchers Should Know in 2026
A scientific overview of Retatrutide and triple receptor agonism: how GLP-1, GIP, and glucagon receptor activity work, why the triple-agonist mechanism matters in metabolic research, what Phase 2 trial data suggests, and how Retatrutide compares to Tirzepatide and Semaglutide.
AI Analyzed 1,000 Retatrutide Discussions: What People Are Really Asking
We analyzed more than 1,000 public Retatrutide discussions to map what researchers and enthusiasts actually ask: the top 10 questions, the Tirzepatide comparison, the biggest fears, the research behind the triple agonist, and where the conversation is heading in 2026.